- Zacks•18 hours ago
Roche Holdings AG (RHHBY) announced that the FDA has approved Ocrevus (ocrelizumab) as the first and only drug for both relapsing and primary progressive forms of multiple sclerosis.
The U.S. Food and Drug Administration (FDA) on Tuesday approved Roche Holding AG's multiple sclerosis (MS) drug Ocrevus, putting the potential blockbuster drug back on track after a delay caused by regulators' concerns over manufacturing issues. The infusible drug, known chemically as ocrelizumab, becomes the first U.S.-approved medicine for the primary progressive form of the neurological disease (PPMS). It is also approved to treat the most common form of the disease, known as relapsing-remitting multiple sclerosis (RRMS).
- Zacks•6 days ago
Roche Holding AG's (RHHBY) member, Genentech announced that the FDA has granted Breakthrough Therapy Designation status to Rituxan (rituximab) for the treatment of pemphigus vulgaris.
RHO.BE : Summary for ROCHE HLDG AG INH. SF 1 - Yahoo Finance
ROCHE HLDG AG INH. SF 1 (RHO.BE)
Berlin - Berlin Delayed Price. Currency in EUR
Add to watchlist
As of 5:15PM CEST. Market open.
|Bid||239.95 x 79100|
|Ask||241.10 x 10000|
|Day's Range||237.57 - 240.83|
|52 Week Range||205.07 - 247.28|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|